Anders Haegerstrand

Born: 1961
Nationality: Swedish
Position: Board member 2018-2020, Chief Executive Officer since 2019

Education and professional experience: Anders Haegerstrand has extensive R&D experience including drug discovery and development as manager at Karolinska Institutet, Astra Pain Control AB and AstraZeneca LLC and within biotech. From year 2000, Anders was CEO and CSO for NeuroNova AB, a leading company in applied stem cell research that brought to protein molecules into Phase I/II clinical studies. The company was later acquired by a listed company, Newron Pharmaceuticals S.p.A., at which Anders was a management team member between 2013 and 2016.

Shareholding in the Company: 1 834 863 shares, 300 000 warrants serie 2022/2025 and 5 000 000 warrants serie 2024/2027.